Head-to-head · Value Score
Trimi Health vs Gala Health
Two GLP-1 deals, scored on the same six factors. Trimi Health lands a Value Score of 89, Gala Health a 86. Here's who gives you the honest lower price — and where each one bites back.
Trimi Health
#7 · Grade A · Great Deal
Est. first month
$99/mo
Save ~93% vs brand-nameGala Health
#15 · Grade A- · Great Deal
Est. first month
$149/mo
Save ~89% vs brand-nameThe verdict
Trimi Health takes it on Value Score, 89 to 86 — an est. $99/mo first month, with no teaser step-up baked in. Gala Health isn't out of it: Tirzepatide-first shoppers in any state who want a rock-bottom compounded entry price and value having a brand-name fallback on the same account.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Trimi Health | Gala Health |
|---|---|---|
| Value Score | 89 (A) | 86 (A-) |
| Est. first month | $99/mo | $149/mo |
| Save vs brand-name | ~93% | ~89% |
| Semaglutide | $99/mo | Not disclosed |
| Tirzepatide | $125/mo | $179/mo |
| Both molecules | Yes | No |
| Pricing | Flat — no step-up | Flat — no step-up |
| Coverage | All 50 states | All 50 states |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Trimi Health
The ultra-budget pick: two-digit semaglutide and a $125 tirzepatide — one of the lowest flat tirz stickers on the whole board — shipped to all 50 states.
Why it's a deal
- Ultra-budget on both molecules — $99 semaglutide and a class-low $125 tirzepatide, flat with no teaser step-up
- Tirzepatide at $125/mo undercuts most of the flat-fee field on the priciest molecule
- Nationwide 50-state reach, so the low price isn't gated to a handful of states
The fine print
- Not LegitScript-certified — do your own pharmacy diligence before you buy on price alone
- Compounded injectable only — no FDA-approved brand-name or oral/sublingual route
- Newer brand with a thin public track record
Gala Health
One of the lowest compounded-tirzepatide entry prices on the board — a $149 microdose tier shipped to all 50 states, with an optional (pricey) brand-name path if you ever need it.
Why it's a deal
- Low compounded-tirzepatide entry — $149/mo microdose, $179/mo full dose, priced flat
- Available in all 50 states, so the low price isn't gated to a few regions
- Offers an FDA-approved brand-name path (Ozempic) alongside compounded, plus HRT/menopause care on the same platform
The fine print
- Compounded medication is not FDA-approved — confirm the 503A/B pharmacy before you buy
- The brand-name option is very expensive at ~$1,299/mo
- No oral/sublingual route yet, and no disclosed compounded semaglutide price
- Newer operator (Gala GLP-1, AI Coaching Inc) with a thin public track record
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.